Since a detailed discussion on the diagnostic approach of the thyroid nodule in general would be beyond the scope of this review, the first part of this paper specifically focuses on the pre-surgical diagnostic approach of thyroid nodules with a significant risk of malignancy. The risk is based on clinical elements, fine-needle aspiration cytology (FNAC) and/or ultrasound (u/s) characteristics. The impact of the work-up on the type and extent of surgery is demonstrated and the cases of 'follicular neoplasm' and papillary thyroid carcinoma (PTC) are highlighted.
Nevertheless, both point to similar additional factors that are taken into account in the decision process: clinical risk factors, the presence/absence of contralateral thyroid nodules and patient preferences. 4, 5 Both the US and European expert panels agree on the indication of a total thyroidectomy in case of clinical suspicion of malignancy (e.g. fixation, hoarseness, etc.) or in the presence of clinical risk factors of malignancy (large tumours >4cm, family history of thyroid cancer, history of radiation exposure). Agreement is also present on the indication of a total thyroidectomy in the presence of bilateral nodular disease and on the importance of the preoperative u/s characteristics (of the nodule as well as the contralateral lobe and lymph nodes (LNs)).
Papillary Thyroid Cancer
As expected, in case of FNAC diagnostic for malignancy -PTC -the ATA guidelines and the ETA consensus agree on the indication of a total thyroidectomy as the standard surgical treatment. Controversy persists, however, regarding the matter of microdissection of LNs. According to the ATA guidelines, routine bilateral central (compartment VI) node dissection "should be considered" for patients with PTC and suspected Hürthle cell cancer, since it may improve survival and reduce recurrences. The European consensus states: "compartment-oriented microdissection of lymph nodes should be performed in cases of pre-operative suspected and/or intraoperatively proven lymph node metastases". Moreover, the result of LN dissection is an important factor in the risk stratification and risk-dependent post-surgical strategy as proposed by the ETA consensus (see below).
Post-surgical Management
The 'Old' Universal Standard
The standard protocol for post-surgical management of DTC, reviewed by Schlumberger et al. 1 and used until recently, is schematically represented in Figure 1 .
The first step is radioiodine ablation (large activity, 100mCi I131) of the thyroid remnant in a setting of thyroid hormone (WD), followed by a total body scan (TBS). Radioiodine remnant ablation is proposed in most patients except in unifocal PTC <1cm.
The second step consists of the evaluation of cure and the long-term surveillance for disease recurrence. Six to 12 months post-surgery, the patient is again withdrawn from thyroid hormone. Four to five weeks later a blood sample is taken to measure serum thyroglobulin (Tg) and a diagnostic dose of radioiodine is administered to evaluate the residual uptake of radioiodine by TBS. In case of uptake outside the thyroid bed, representing residual disease, further treatment is indicated. Fortunately, in the majority of patients no, or very limited, residual uptake in the thyroid bed is present. In this case, the serum Tg level should be evaluated, serving as a tumour marker. An undetectable level (<1ng/ml) indicates cure, whereas a Tg (10ng/ml indicates a high risk of residual disease and need for further investigation/treatment. In case of an intermediate value (1-10ng/ml) follow-up is warranted, since one-third of these patients will progress with rising Tg levels if the procedure is repeated after two years. Two-thirds of this patient group do not progress and their Tg level will decline, probably as a late consequence of the initial radioiodine therapy.
This scheme can be called the universal standard for post-surgical followup, since published outcome data are in agreement with this protocol. 2, 3 On the other hand, this scheme could be called the hard old standard, including repeated (at least two) episodes of hypothyroidism (being inconvenient for the patient) and lifelong TSH-suppressive therapy (not only being hardly tolerable for several patients, but also increasing the risk of osteoporosis and cardiac arrhythmia).
Refinements and New Tools Introduced in the Last Decade
Two major advances in recent years have enabled clinicians and patients to avoid some inconveniences of the previous management protocol: recombinant human TSH (rhTSH) and u/s.
ATA Guidelines and ETA Consensus Regarding rhTSH and its Indications
With the development of rhTSH, it is nowadays possible to reach increased TSH levels, with the difference being that TSH is not endogenously produced but exogenously administered, allowing continuation of the thyroid hormone treatment. Two injections of rhTSH (Thyrogen ® 0.9mg, Genzyme Corporation, Cambridge, Mass.) result in TSH levels comparable to the levels obtained after WD. Side effects are minor, and the major side effects of WD -symptomatic hypothyroidism -can be avoided. 12 According to the universal standard, two episodes of high TSH are needed. In step one -the therapeutic step -high TSH necessarily
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precedes treatment with a high dose of radioiodine, aiming at maximal radioiodine uptake by the remnant tissue. In step two -the diagnostic step -high TSH is needed for optimal iodine uptake (TBS) or Tg production (serum Tg measurement) by remaining local or distant cancer cells. In both the diagnostic and therapeutic steps, rhTSH had to prove its equivalency to the withdrawal method before its approval.
Concerning the diagnostic use of rhTSH, a randomised study showed that rhTSH and WD are equally sensitive and specific for the detection of residual or recurrent DTC. This is the case provided a lower cut-off value for Tg is used after rhTSH compared with the cut-off values used after WD. The inpatient comparison showed that Tg values after WD of 10ng/ml correspond to values between 2 and 5ng/ml after rTSH. 13 The diagnostic use of rhTSH has been included in the ATA guidelines and the ETA consensus.
Concerning the therapeutic use of rhTSH, there is one randomised study limited to low-risk patients. This study shows equal ablation rates in both groups. 14 The therapeutic use of rhTSH has been approved by the European Medicines Agency and was introduced in the ETA consensus for low-risk patients. In the flow chart proposed by the ATA, the therapeutic use of rhTSH is proposed as an alternative to WD. The footnotes are more restrictive since the therapeutic use is not approved by the US Food and Drug Administration (FDA) and since the majority of the authors retrieved themselves from the discussion because of varying degrees of involvement with the Genzyme Corporation, the manufacturer of rhTSH (Thyrogen ® ).
The Role of Ultrasound in Post-operative Follow-up
A sensitive method to locate residual or recurrent LN disease is u/s. The reported sensitivity varies between 90 and 96%. 8, 9 For LN disease, u/s is even more sensitive than diagnostic TBS. The problem with u/s lies in its lack of specificity and the difficulties in discerning metastatic from reactive LNs. In order to obtain proof that the LN demonstrated by u/s is metastatic, FNAC can be performed. However, this technique raises the problem of frequent inadequate samples and therefore should be completed with the collection of the needle-washout for detection of Tg. 15, 16 Due to its very high sensitivity to detect neck recurrences, u/s has been introduced in post-operative follow-up algorithms. According to the ATA guidelines, u/s is considered the number one examination in the follow-up of the majority of DTC cases, combined with a serum Tg measurement three months after ablation. No explicit description is mentioned where u/s findings alter the management. 4 Also, in the algorithm proposed by the ETA, u/s is high in the ranking of examinations and accompanies the rhTSH-stimulated Tg value in the planning of follow-up (see Figure 2) . In this consensus report, the authors advise u/sguided FNAC for suspicious findings >0.5cm and u/s follow-up some months later for suspicious findings ≤0.5cm. 5 However, the procedure of the FNAC samples is not mentioned and the advice of the authors is, probably, a FNAC for conventional cytology supplemented by determination of Tg in the needle-washout.
Risk-tailored Strategy -Resulting in a New

Standard Protocol
Contrary to the universal standard post-surgical management, which is risk-independent (except for the exclusion of unifocal microPTC), the recent European consensus and ATA guideline standard take into account the very initial staging, determining the indication (and procedure) for ablation of the thyroid remnant.
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Risk-dependent Strategy
The indication and method of ablation as proposed by the ETA consensus and ATA guideline paper respectively is schematically represented in Table 1 .
Regarding the European consensus, two patient groups have to be discerned: the high-risk and the low-risk patient group. In the high-risk patient group, radioiodine has been proved to reduce the recurrence and mortality risk and in this group the indication for the 'old' standard ablation (≥100mCi after WD) is definite. In the low-risk group, however, the goal of ablation consists in reduction of the recurrence risk and improvement of diagnostic accuracy (see Table 2 ). In this group, the assumption is that preparatory rhTSH and/or a lower radioiodine activity is probably as good as the 'old' standard ablation.
The ATA guideline indicates radioiodine ablation depending on the Tumor, Node, Metastases/American Joint Committee on Cancer, sixth edition (2002) risk groups and is therefore more restrictive regarding the use of rhTSH (see above).
Step Two -The New Follow-up Schemes
Exemplified by the follow-up scheme of the ETA consensus paper (see Figure 2 ), rhTSH-stimulated Tg and u/s are central to the follow-up as described above. The rhTSH-stimulated Tg cut-off value indicating a high risk of residual disease and need for immediate imaging and/or treatment is called 'institutional'. In the text a rhTSH-stimulated Tg value of ≥2ng/ml is proposed.
TSH Substitution-Suppression Therapy
Treatment phase and risk group are the determinants for the proposed TSH goal (see Table 3 ).
Conclusion
The All of these advances aim at a total removal of the tumour at the first surgery, allowing accurate staging that determines the following risk-dependent strategy and follow-up, thereby minimising the risk of recurrence, metastasis or cancer-related death on the one hand, but also minimising unnecessary side effects of treatment on the other hand. ■ Thyroid Disorders
